Literature DB >> 10581170

The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.

A Kanatani1, T Kanno, A Ishihara, M Hata, A Sakuraba, T Tanaka, Y Tsuchiya, T Mase, T Fukuroda, T Fukami, M Ihara.   

Abstract

Neuropeptide Y (NPY) is known to induce robust feeding through the action of NPY receptors in the hypothalamus. Among the subtypes of NPY receptors, Y(1) receptors may play a key role in feeding regulation. In the present study, we demonstrated that a novel Y(1) antagonist, J-104870, shows high selectivity and potency for the Y(1) receptor with an anorexigenic effect on NPY-mediated feeding. J-104870 displaced [(125)I]peptide YY (PYY) binding to cloned human and rat Y(1) receptors with K(i) values of 0.29 and 0.54 nM, respectively, and inhibited the NPY (10 nM)-induced increase in intracellular calcium levels (IC(50) = 3.2 nM) in cells expressing human Y(1) receptors. In contrast, J-104870 showed low affinities for human Y(2) (K(i) > 10 microM), Y(4) (K(i) > 10 microM), and Y(5) receptors (K(i) = 6 microM). In rat hypothalamic membranes, J-104870 also completely displaced the binding of [(125)I]1229U91, which is known to bind to the typical Y(1) receptor, with a high affinity (K(i) = 2.0 nM). Intracerebroventricular (ICV) injection of J-104870 (200 microg) significantly suppressed NPY (5 microg)-induced feeding in satiated Sprague-Dawley rats by 74%. Furthermore, ICV and oral administration of J-104870 (200 microg and 100 mg/kg, respectively) significantly suppressed spontaneous food intake in Zucker fatty rats. These findings suggested that J-104870 is a selective and potent nonpeptide Y(1) antagonist with oral bioavailability and brain penetrability. In addition, the anorexigenic effect of J-104870 clearly revealed the participation of the Y(1) receptor in NPY-mediated feeding regulation. The potent and orally active Y(1) antagonist J-104970 is a useful tool for elucidating the physiological roles of NPY in obesity. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10581170     DOI: 10.1006/bbrc.1999.1750

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform.

Authors:  Marianne Rodriguez; Valérie Audinot; Sandra Dromaint; Christelle Macia; Véronique Lamamy; Philippe Beauverger; Hervé Rique; Jérôme Imbert; Jean Paul Nicolas; Jean A Boutin; Jean Pierre Galizzi
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

Review 3.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 4.  New targets to treat obesity and the metabolic syndrome.

Authors:  Kathleen A Martin; Mitra V Mani; Arya Mani
Journal:  Eur J Pharmacol       Date:  2015-05-19       Impact factor: 4.432

5.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

6.  Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.

Authors:  Shuanghua Hu; Yazhong Huang; Milind Deshpande; Guanglin Luo; Marc A Bruce; Ling Chen; Gail Mattson; Lawrence G Iben; Jie Zhang; John W Russell; Wendy J Clarke; John B Hogan; Astrid Ortiz; Oliver Flint; Andrew Henwood; Qi Gao; Ildiko Antal-Zimanyi; Graham S Poindexter
Journal:  ACS Med Chem Lett       Date:  2012-01-04       Impact factor: 4.345

7.  Distribution of peripherally injected peptide YY ([125I] PYY (3-36)) and pancreatic polypeptide ([125I] hPP) in the CNS: enrichment in the area postrema.

Authors:  Yvan Dumont; Emmanuel Moyse; Alain Fournier; Rémi Quirion
Journal:  J Mol Neurosci       Date:  2007-09-18       Impact factor: 3.444

Review 8.  Pathophysiology of obesity: why surgery remains the most effective treatment.

Authors:  Talat Waseem; Kris M Mogensen; David B Lautz; Malcolm K Robinson
Journal:  Obes Surg       Date:  2007-10       Impact factor: 4.129

9.  Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion.

Authors:  John M Stafford; Fang Yu; Richard Printz; Alyssa H Hasty; Larry L Swift; Kevin D Niswender
Journal:  Diabetes       Date:  2008-03-10       Impact factor: 9.461

10.  Peripheral and central administration of a selective neuropeptide Y Y1 receptor antagonist suppresses ethanol intake by C57BL/6J mice.

Authors:  Dennis R Sparta; Jon R Fee; Dayna M Hayes; Darin J Knapp; Douglas J MacNeil; Todd E Thiele
Journal:  Alcohol Clin Exp Res       Date:  2004-09       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.